



State of Vermont
Department of Vermont Health Access
NOB 1 South, 280 State Drive
Waterbury, VT 05671-1010

Agency of Human Services
[Phone] 802-879-5900
[Fax] 802-241-0268

August 20, 2020

****Important Changes to Buprenorphine/Naloxone Tablet PDL Status****

Dear Medicaid Provider,

Due to recent changes in the Medicaid net cost of Medication Assisted Treatment (MAT) drugs, the Department of Vermont Health Access (DVHA) is making some immediate changes to the Preferred Drug List (PDL). **Effective 8/21/20**, generic buprenorphine/naloxone combination **tablets** will be moving to preferred status and will be co-preferred with Suboxone® Film. To align with the Suboxone® Film criteria, a prior authorization will not be required for the combination tablets unless the maximum daily dose exceeds 16mg.

Please note that Buprenorphine/naloxone tablets are not a generic formulation of Suboxone® films, therefore, the pharmacist may not automatically substitute. If you wish to switch your patients from Suboxone® films to buprenorphine/naloxone tablets, a new prescription must be written.

Non-preferred formulations of buprenorphine include generic buprenorphine/naloxone *films*, generic buprenorphine tablets, Zubsolv®, and Bunavail®. These non-preferred drugs will continue to require a prior authorization submission.

For questions, please contact the Change Healthcare Pharmacy Help Desk at 1-844-679-5362. Vermont providers can also send inquiries via email to **PBA_VTHelpdesk@changehealthcare.com**. Thank you for your continued support of Vermont's clinical pharmacy programs.

Nancy J. Hogue, Pharm.D.

Director of Pharmacy Services